{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:05:04Z","timestamp":1791515104489,"version":"4.3.4"},"reference-count":175,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The aberrant localization of the mutated nucleophosmin (NPM1) protein in the cytoplasm is the hallmark of the development of acute myeloid leukemia (AML); the gene, located in the nucleolus, codes for a protein that normally shuttles between the nucleus and the cytoplasm of the normal hematopoietic cells. Patients harboring NPM1 mutations are diagnosed as having NPM1-mutated AMLs, which are types of leukemia with distinct clinical and laboratory characteristics. The essential diagnostics for investigating NPM1-mutated AMLs, the interactions with concomitant mutations affecting prognosis and the therapeutic interventions that the treatment of such patients requires are discussed in this review. Novel investigational agents in current clinical trials are also highlighted, along with the roles of exportin 1 (XPO1), menin-KMT2A inhibitors and immunotherapy in NPM1-mutated AMLs. This review focuses on critically evaluating the available data and aims to reveal the secrets of NPM1-mutated AMLs.<\/jats:p>","DOI":"10.3390\/cancers17132095","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:42:34Z","timestamp":1750664554000},"page":"2095","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["NPM1-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment Strategies"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0041-5930","authenticated-orcid":false,"given":"Michael D.","family":"Diamantidis","sequence":"first","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Smaragdi","family":"Vlachou","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Katsikavela","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smaragdi","family":"Kalomoiri","sequence":"additional","affiliation":[{"name":"Department of Hematology-Lymphoma, Bone Marrow Transplantation Unit, Evangelismos General Hospital, 10676 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Bartzi","sequence":"additional","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Ikonomou","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Prevention Unit, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood-2006-03-007013","article-title":"Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia","volume":"108","author":"Falini","year":"2006","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hindley, A., Catherwood, M.A., McMullin, M.F., and Mills, K.I. (2021). Significance of NPM1 Gene Mutations in AML. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810040"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ajh.26989","article-title":"NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions","volume":"98","author":"Falini","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Box, J.K., Paquet, N., Adams, M.N., Boucher, D., Bolderson, E., O\u2019Byrne, K.J., and Richard, D.J. (2016). Nucleophosmin: From structure and function to disease development. BMC Mol. Biol., 17.","DOI":"10.1186\/s12867-016-0073-9"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zarka, J., Short, N.J., Kanagal-Shamanna, R., and Issa, G.C. (2020). Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. Genes, 11.","DOI":"10.3390\/genes11060649"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: From bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12185-018-02578-7","article-title":"New insights into the biology of acute myeloid leukemia with mutated NPM1","volume":"110","author":"Brunetti","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cela, I., Di Matteo, A., and Federici, L. (2020). Nucleophosmin in Its Interaction with Ligands. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144885"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.2020008211","article-title":"How I diagnose and treat NPM1-mutated AML","volume":"137","author":"Falini","year":"2021","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/s41375-021-01222-4","article-title":"Diagnostic and therapeutic pitfalls in NPM1-mutated AML: Notes from the field","volume":"35","author":"Falini","year":"2021","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.26862","article-title":"Mutant NPM1: Nuclear export and the mechanism of leukemogenesis","volume":"98","author":"Falini","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.blre.2017.11.001","article-title":"When the good go bad: Mutant NPM1 in acute myeloid leukemia","volume":"32","author":"Kunchala","year":"2018","journal-title":"Blood Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2015.133819","article-title":"Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia","volume":"101","author":"Alpermann","year":"2016","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bailey, G.D., Doolan, L., Baskar, A., Smith, L.C., and Seedhouse, C.H. (2020). Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-73782-x"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2023). Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias. Biomedicines, 11.","DOI":"10.20944\/preprints202305.1258.v1"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tregnago, C., Benetton, M., Padrin, D., Polato, K., Borella, G., Da Ros, A., Marchetti, A., Porc\u00f9, E., Del Bufalo, F., and Mecucci, C. (2021). NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML. Cancers, 13.","DOI":"10.3390\/cancers13143457"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dolnik","year":"2018","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-018-0566-8","article-title":"Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population","volume":"11","author":"Wei","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2005-04-1733","article-title":"Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia","volume":"106","author":"Suzuki","year":"2005","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1532\/IJH97.A10620","article-title":"Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia","volume":"86","author":"Yan","year":"2007","journal-title":"Int. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: A multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2013","journal-title":"Lancet. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of Acute Myeloid Leukemia Diagnosis and Pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1182\/bloodadvances.2022007544","article-title":"High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML","volume":"6","author":"Larkin","year":"2022","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/2159-8290.CD-20-1579","article-title":"Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia","volume":"11","author":"Bhatnagar","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in Acute Myeloid Leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101156","DOI":"10.1016\/j.blre.2023.101156","article-title":"Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia","volume":"64","author":"Chandra","year":"2023","journal-title":"Blood Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/ng.796","article-title":"Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice","volume":"43","author":"Vassiliou","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/bloodadvances.2022007015","article-title":"Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice","volume":"7","author":"Muranyi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MOH.0000000000000480","article-title":"Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia","volume":"26","author":"Zuckerman","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.17185","article-title":"How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)","volume":"193","author":"Dillon","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/hematology.2024000542","article-title":"Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient","volume":"2024","author":"Heuser","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/hematology.2023000454","article-title":"Understanding differential technologies for detection of MRD and how to incorporate into clinical practice","volume":"2023","author":"Cloos","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022226","article-title":"MRD in AML: Who, what, when, where, and how?","volume":"143","author":"Sahasrabudhe","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1182\/bloodadvances.2022007420","article-title":"The antagonistic duality of NPM1 mutations in AML","volume":"6","author":"Khan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood.2018862383","article-title":"Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML","volume":"134","author":"Garg","year":"2019","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/ijlh.14133","article-title":"Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients","volume":"45","author":"Chen","year":"2023","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2009-01-197871","article-title":"AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features","volume":"114","author":"Haferlach","year":"2009","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/16078454.2022.2071799","article-title":"Molecular genetic and clinical characterization of acute myeloid leukemia with trisomy 8 as the sole chromosome abnormality","volume":"27","author":"Liu","year":"2022","journal-title":"Hematology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2011.01710.x","article-title":"Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations","volume":"88","author":"Larsson","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.2022.281137","article-title":"Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/gcc.22418","article-title":"Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4","volume":"56","author":"Herold","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: Another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy","volume":"22","author":"Ross","year":"2017","journal-title":"Oncologist"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/0008-5472.CAN-14-1576","article-title":"Therapeutically Targetable ALK Mutations in Leukemia","volume":"75","author":"Maxson","year":"2015","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Shekar, M., Llaurador Caraballo, G., Punia, J.N., Curry, C.V., Fisher, K.E., and Redell, M.S. (2023). ALK Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071842"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e30180","DOI":"10.1002\/pbc.30180","article-title":"Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia","volume":"70","author":"Manselle","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sharma, N., and Liesveld, J.L. (2023). NPM 1 Mutations in AML-The Landscape in 2023. Cancers, 15.","DOI":"10.3390\/cancers15041177"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1002\/cncr.24610","article-title":"Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation","volume":"115","author":"Chen","year":"2009","journal-title":"Cancer"},{"key":"ref_64","first-page":"15","article-title":"NPM1 and FLT3-ITD\/TKD Gene Mutations in Acute Myeloid Leukemia","volume":"15","author":"Naseem","year":"2021","journal-title":"Int. J. Hematol.-Oncol. Stem Cell Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41417-018-0013-6","article-title":"Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5","volume":"25","author":"Cheng","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, B., Yang, B., Wu, W., Liu, X., and Li, H. (2021). The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08455-7"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation","volume":"96","author":"Raponi","year":"2011","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.leu.2404857","article-title":"Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: Implications for the cell of origin of NPMc+ AML","volume":"22","author":"Martelli","year":"2008","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.leu.2404597","article-title":"Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation","volume":"21","author":"Albiero","year":"2007","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1182\/blood.2021012732","article-title":"Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML","volume":"138","author":"Martelli","year":"2021","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1038\/sj.onc.1209453","article-title":"Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal","volume":"25","author":"Mariano","year":"2006","journal-title":"Oncogene"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2023-185321","article-title":"Venetoclax has potent efficacy in NPM1 mutated AML with acquired resistance associated with either perturbed pro-survival signalling or NPM1 wild-type populations","volume":"142","author":"Chua","year":"2023","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2024014900","article-title":"Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)","volume":"9","author":"Chua","year":"2025","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e2023032","DOI":"10.4084\/MJHID.2023.032","article-title":"Genetic Predisposition to Hematologic Malignancies in Childhood and Adolescence","volume":"15","author":"Fabozzi","year":"2023","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2021011354","article-title":"Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML","volume":"139","author":"Yang","year":"2022","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood.2023020209","article-title":"Prevalence and significance of DDX41 gene variants in the general population","volume":"142","author":"Gu","year":"2023","journal-title":"Blood"},{"key":"ref_77","first-page":"607","article-title":"Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML","volume":"138","author":"Lachowiez","year":"2021","journal-title":"Blood ASH Annu. Meet. Abstr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Pratz","year":"2024","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_86","first-page":"529","article-title":"Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood ASH Annu. Meet. Abstr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41375-020-0872-3","article-title":"Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged\u2009<60 years","volume":"34","author":"Eisfeld","year":"2020","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajh.26694","article-title":"Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment","volume":"97","author":"Lachowiez","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia"},{"key":"ref_93","first-page":"225","article-title":"Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission","volume":"138","author":"Fleming","year":"2021","journal-title":"Blood ASH Annu. Meet. Abstr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2023-186160","article-title":"Secondary-type mutations do not impact the favorable outome of NPM1-mutated acute myeloid leukemia patients-results from a large cohort of intensively treated patients","volume":"142","author":"Bill","year":"2023","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","article-title":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia-implications for the European LeukemiaNet risk classification","volume":"37","author":"Eckardt","year":"2023","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2023-179598","article-title":"Influence of bone marrow blast enumeration and co-occuring myelodysplasia related gene mutations in NPM1-mutated myeloid malignancies","volume":"142","author":"Lachowiez","year":"2023","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wang, Y., Quesada, A.E., Zuo, Z., Medeiros, L.J., Yin, C.C., Li, S., Xu, J., Borthakur, G., Li, Y., and Yang, C. (2022). The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. Cancers, 15.","DOI":"10.3390\/cancers15010198"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1002\/ajh.26730","article-title":"Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1","volume":"97","author":"Wright","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"106869","DOI":"10.1016\/j.leukres.2022.106869","article-title":"NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS\/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1","volume":"118","author":"Zhao","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: An Alliance study","volume":"37","author":"Kohlschmidt","year":"2023","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e70060","DOI":"10.1002\/hem3.70060","article-title":"Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML","volume":"9","author":"Cocciardi","year":"2025","journal-title":"Hemasphere"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(00)80370-0","article-title":"Exportin 1 (Crm1p) is an essential nuclear export factor","volume":"90","author":"Stade","year":"1997","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1182\/bloodadvances.2022007563","article-title":"Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML","volume":"6","author":"Pianigiani","year":"2022","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","article-title":"Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance","volume":"106","author":"Alcalay","year":"2005","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","article-title":"HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis","volume":"34","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Chen, S.L., Qin, Z.Y., Hu, F., Wang, Y., Dai, Y.J., and Liang, Y. (2019). The Role of the HOXA Gene Family in Acute Myeloid Leukemia. Genes, 10.","DOI":"10.3390\/genes10080621"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/leu.2015.194","article-title":"Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice","volume":"30","author":"Etchin","year":"2016","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/bloodadvances.2019000359","article-title":"Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies","volume":"4","author":"Fischer","year":"2020","journal-title":"Blood Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/jcmm.17274","article-title":"Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia","volume":"26","author":"Yu","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/ITT.S429402","article-title":"Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes","volume":"12","author":"Jiang","year":"2023","journal-title":"Immunotargets Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-023-01882-4","article-title":"Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1","volume":"37","author":"Mill","year":"2023","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 Maintains the Leukemic State through HOX Expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_116","first-page":"150","article-title":"The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study","volume":"140","author":"Issa","year":"2022","journal-title":"Blood ASH Annu. Meet. Abstr."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R\/R) KMT2Ar Acute Leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. of. Clinical. Oncology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/bloodadvances.2021005736","article-title":"KMT2A-CBL rearrangements in acute leukemias: Clinical characteristics and genetic breakpoints","volume":"5","author":"Bataller","year":"2021","journal-title":"Blood Adv."},{"key":"ref_120","first-page":"891","article-title":"Safety and activity of Revumenib in combination with fludarabine\/cytarabine (FLA) in patients with relapsed\/refractory acute leukemias (P540)","volume":"8","author":"Shukla","year":"2024","journal-title":"HemaSphere"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib Combined with Venetoclax\/Azacitidine in Relapsed\/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): A randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"Weber","year":"2023","journal-title":"Lancet. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Schlenk, R.F., Weber, D., Krzykalla, J., Kindler, T., Wulf, G., Hertenstein, B., Salih, H.R., S\u00fcdhoff, T., Krauter, J., and Martens, U. (2023). Randomized phase-III study of low-dose cytarabine and etoposide\u2009+\u2009\/- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-41964-y"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41375-024-02335-2","article-title":"Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia-a FILO study","volume":"38","author":"Orvain","year":"2024","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 Results: First-in-Human Phase 1\/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1527.1521","DOI":"10.1182\/blood-2024-198164","article-title":"Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML- the SAL\/AMLCG Vincent Trial","volume":"144","author":"Kretschmer","year":"2024","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2024-210315","article-title":"Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial","volume":"144","author":"Sartor","year":"2024","journal-title":"Blood"},{"key":"ref_130","first-page":"153","article-title":"Update on a Phase 1\/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia","volume":"140","author":"Erba","year":"2022","journal-title":"Blood ASH Annu. Meet. Abstr."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2024-198218","article-title":"Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood.V92.5.1768","article-title":"Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid","volume":"92","author":"Hu","year":"1998","journal-title":"Blood"},{"key":"ref_135","first-page":"1667","article-title":"Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells","volume":"9","author":"Hu","year":"1995","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1182\/blood-2010-09-309674","article-title":"Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1","volume":"118","author":"Balusu","year":"2011","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2014-11-611459","article-title":"Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells","volume":"125","author":"Martelli","year":"2015","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2014-11-612416","article-title":"Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells","volume":"125","author":"Dassouki","year":"2015","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2015-04-636217","article-title":"ATRA and ATO team up against NPM1","volume":"125","author":"Grant","year":"2015","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2009-08-236588","article-title":"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: Overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA","volume":"115","author":"Burnett","year":"2010","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-016-2810-z","article-title":"All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: Results of the randomized AMLSG 07-04 study","volume":"95","author":"Schlenk","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","article-title":"Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia","volume":"18","author":"Schlenk","year":"2004","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1182\/bloodadvances.2023010559","article-title":"Vitamin C and D supplementation in acute myeloid leukemia","volume":"7","author":"Mouchel","year":"2023","journal-title":"Blood Adv."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: Results from the AMLSG 09-09 trial","volume":"136","author":"Weber","year":"2020","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_151","first-page":"147","article-title":"Optimal post-remission consolidation therapy in patients with AML","volume":"147","author":"Dillon","year":"2023","journal-title":"Acta Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"New Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.18887","article-title":"A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure","volume":"202","author":"Sartor","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","article-title":"STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Greiner, J., Mohamed, E., Fletcher, D.M., Schuler, P.J., Schrezenmeier, H., G\u00f6tz, M., and Guinn, B.A. (2024). Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia. Cancers, 16.","DOI":"10.20944\/preprints202406.1388.v1"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Abaza, Y., and Zeidan, A.M. (2022). Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cells, 11.","DOI":"10.3390\/cells11142249"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"101247","DOI":"10.1016\/j.beha.2021.101247","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia","volume":"34","author":"Daver","year":"2021","journal-title":"Best. Pr. Res. Clin. Haematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.V128.22.763.763","article-title":"Phase IB\/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2024-210370","article-title":"Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)","volume":"144","author":"Stempel","year":"2024","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2010-07-297143","article-title":"A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia","volume":"117","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3324\/haematol.2018.199794","article-title":"Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options-results from a phase I study","volume":"104","author":"Fiedler","year":"2019","journal-title":"Haematologica"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","article-title":"Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial","volume":"5","author":"Pabst","year":"2021","journal-title":"Blood Adv."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Guinn, B.A., Schuler, P.J., Schrezenmeier, H., Hofmann, S., Weiss, J., Bulach, C., G\u00f6tz, M., and Greiner, J. (2023). A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119285"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Skayneh, H., Jishi, B., Hleihel, R., Hamie, M., El Hajj, R., Deleuze-Masquefa, C., Bonnet, P.A., El Sabban, M., and El Hajj, H. (2022). EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3\/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073421"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Makhoul, P., Hleihel, R., Itani, S., Hamie, M., Pagniagua-Gayraud, S., Patinote, C., Richaud, M., Merhi, R.A., El-Sabban, M., and Galas, S. (2025). The Novel Imiqualine EAPB02303 Is a Potent Drug for Treating Acute Myeloid Leukemia. Biomolecules, 15.","DOI":"10.3390\/biom15050741"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Mardiana, S., and Gill, S. (2020). CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00697"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","article-title":"CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success","volume":"35","author":"Fiorenza","year":"2021","journal-title":"BioDrugs"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e2122379119","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Wang, R., Xu, P., Chang, L.L., Zhang, S.Z., and Zhu, H.H. (2022). Targeted therapy in NPM1-mutated AML: Knowns and unknowns. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.972606"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Perriello, V.M., Gionfriddo, I., Rossi, R., Milano, F., Mezzasoma, F., Marra, A., Spinelli, O., Rambaldi, A., Annibali, O., and Avvisati, G. (2021). CD123 Is Consistently Expressed on NPM1-Mutated AML Cells. Cancers, 13.","DOI":"10.3390\/cancers13030496"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/bloodadvances.2022008762","article-title":"IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML","volume":"7","author":"Perriello","year":"2023","journal-title":"Blood Adv."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"Reijmers","year":"2019","journal-title":"J. Clin. Investig."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:57:05Z","timestamp":1760032625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":175,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132095"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132095","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}